Top

Published in:

Open Access 01-12-2023 | Research

A combined analysis of multi-omics data reveals the prognostic values and immunotherapy response of LAG3 in human cancers

Authors: Jinwu Peng, Zhihao Du, Yuwei Sun, Zhiyang Zhou

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Lymphocyte-activation gene 3 (LAG3) is a highly anticipated immune checkpoint in the context of cancer, exerting regulatory control over immune cell proliferation and function to reinforce the advancement of cancers. However, the comprehensive functional analysis of LAG3 across various cancer types remains undisclosed; thus, this study aims to investigate the pan-cancer expression profile of LAG3. We have investigated the expression profile, prognostic significance, and genetic alterations of LAG3 in various cancers while elucidating its characteristic in immune response regulation. Our findings demonstrated that elevated LAG3 expression is significantly associated with favorable prognosis in patients with cutaneous melanoma (SKCM), and it may be a potential biomarker for SKCM. Furthermore, multiple immune algorithms have highlighted the important regulatory role of LAG3 for the tumor-infiltrating immune cells including CD8 + T cells, B cells, dendritic cells (DCs), macrophages, and natural killer (NK) cells. We also examined the distribution of LAG3 at the single-cell level and explored its functional significance. A comprehensive and systematic analysis of LAG3 would facilitate a comprehensive evaluation of LAG3 in cancer biology and provide valuable insights for cancer management.

Available only for authorised users

Li Y, Lin Y, Aye L, Dong L, Zhang C, Chen F, Liu Y, Fan J, Gao Q, Lu H, et al. An integrative pan-cancer analysis of the molecular and biological features of glycosyltransferases. Clin Transl Med. 2022;12(7): e872.CrossRefPubMedPubMedCentral

Ren L, Yi J, Yang Y, Li W, Zheng X, Liu J, Li S, Yang H, Zhang Y, Ge B, et al. Systematic pan-cancer analysis identifies APOC1 as an immunological biomarker which regulates macrophage polarization and promotes tumor metastasis. Pharmacol Res. 2022;183: 106376.CrossRefPubMed

Wang M, Du Q, Jin J, Wei Y, Lu Y, Li Q. LAG3 and its emerging role in cancer immunotherapy. Clin Transl Med. 2021;11(3): e365.CrossRefPubMedPubMedCentral

Hu Y, Paris S, Bertolet G, Barsoumian HB, He K, Sezen D, Chen D, Wasley M, Silva JD, Mitchell JA, et al. Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer. J Nanobiotechnology. 2022;20(1):417.CrossRefPubMedPubMedCentral

Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80–96.CrossRefPubMedPubMedCentral

Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010;107(17):7875–80.CrossRefPubMedPubMedCentral

Liu Q, Qi Y, Zhai J, Kong X, Wang X, Wang Z, Fang Y, Wang J. Molecular and clinical characterization of LAG3 in breast cancer through 2994 samples. Front Immunol. 2021;12: 599207.CrossRefPubMedPubMedCentral

Ulase D, Behrens HM, Kruger S, Heckl SM, Ebert U, Becker T, Rocken C. LAG3 in gastric cancer: it’s complicated. J Cancer Res Clin Oncol. 2023;149(12):10797–811.CrossRefPubMedPubMedCentral

Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutierrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24–34.CrossRefPubMedPubMedCentral

10.

Shao D, Chen Y, Huang H, Liu Y, Chen J, Zhu D, Zheng X, Chen L, Jiang J. LAG3 blockade coordinates with microwave ablation to promote CD8(+) T cell-mediated anti-tumor immunity. J Transl Med. 2022;20(1):433.CrossRefPubMedPubMedCentral

11.

Gulhati P, Schalck A, Jiang S, Shang X, Wu CJ, Hou P, Ruiz SH, Soto LS, Parra E, Ying H, et al. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nat Cancer. 2023;4(1):62–80.PubMed

12.

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–14.CrossRefPubMedPubMedCentral

13.

Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–60.CrossRefPubMedPubMedCentral

14.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.CrossRefPubMed

15.

Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva NT, Legeay M, Fang T, Bork P, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49(D1):D605-d612.CrossRefPubMed

16.

Yuan H, Yan M, Zhang G, Liu W, Deng C, Liao G, Xu L, Luo T, Yan H, Long Z, et al. CancerSEA: a cancer single-cell state atlas. Nucleic Acids Res. 2019;47(D1):D900–8.CrossRefPubMed

17.

Han Y, Wang Y, Dong X, Sun D, Liu Z, Yue J, Wang H, Li T, Wang C. TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment. Nucleic Acids Res. 2023;51(D1):D1425–31.CrossRefPubMed

18.

Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19(1):37–50.CrossRefPubMed

19.

MacLachlan BJ, Mason GH, Greenshields-Watson A, Triebel F, Gallimore A, Cole DK, Godkin A. Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor. Eur J Immunol. 2021;51(2):331–41.CrossRefPubMed

20.

Turnis ME, Andrews LP, Vignali DA. Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol. 2015;45(7):1892–905.CrossRefPubMedPubMedCentral

21.

Huard B, Tournier M, Hercend T, Triebel F, Faure F. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. Eur J Immunol. 1994;24(12):3216–21.CrossRefPubMed

22.

Somasundaram A, Cillo AR, Lampenfeld C, Workman CJ, Kunning S, Oliveri L, Velez M, Joyce S, Calderon M, Dadey R, et al. Systemic immune dysfunction in cancer patients driven by IL6 induction of LAG3 in peripheral CD8+ T cells. Cancer Immunol Res. 2022;10(7):885–99.CrossRefPubMedPubMedCentral

23.

Tu L, Guan R, Yang H, Zhou Y, Hong W, Ma L, Zhao G, Yu M. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival. Int J Cancer. 2020;147(2):423–39.CrossRefPubMed

24.

Xia ZA, Lu C, Pan C, Li J, Li J, Mao Y, Sun L, He J. The expression profiles of signature genes from CD103(+)LAG3(+) tumour-infiltrating lymphocyte subsets predict breast cancer survival. BMC Med. 2023;21(1):268.CrossRefPubMedPubMedCentral

25.

Workman CJ, Dugger KJ, Vignali DA. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol. 2002;169(10):5392–5.CrossRefPubMed

26.

Chocarro L, Blanco E, Zuazo M, Arasanz H, Bocanegra A, Fernandez-Rubio L, Morente P, Fernandez-Hinojal G, Echaide M, Garnica M, et al. Understanding LAG-3 signaling. Int J Mol Sci. 2021;22(10):5282.CrossRefPubMedPubMedCentral

Title: A combined analysis of multi-omics data reveals the prognostic values and immunotherapy response of LAG3 in human cancers
Authors: Jinwu Peng
Zhihao Du
Yuwei Sun
Zhiyang Zhou
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01583-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A combined analysis of multi-omics data reveals the prognostic values and immunotherapy response of LAG3 in human cancers

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Functional independence, frailty and perceived quality of life in patients who developed delirium during ICU stay: a prospective cohort study

Evaluation of the safety and efficacy of extracorporeal carbon dioxide removal in the critically ill using the PrismaLung+ device

The association of body mass index and weight waist adjustment index with serum ferritin in a national study of US adults

Cardiometabolic-related dietary patterns and thyroid function: a population-based cross-sectional study

Contrast media extravasation injury: a prospective observational cohort study

Development and validation a model for predicting overall survival of bladder cancer with lung metastasis: a population-based study